Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for prevention of taxane-induced neuropathy in breast cancer
IRCT20160310026998N9Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of memantine in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Taxane-induced neuropathy intensity. Started Feb 2019; status: completed.
02
Drugs
memantine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on IRCT20160310026998N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160310026998N9.